Get the Stockscreener App
1.71
4.91%
0.08
Prelude Therapeutics Inc stock is traded at $1.71, with a volume of 339.85K.
It is up +4.91% in the last 24 hours and up +16.33% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$1.63
Open:
$1.615
24h Volume:
339.85K
Relative Volume:
0.26
Market Cap:
$107.50M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.9607
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
+17.12%
1M Performance:
+16.33%
6M Performance:
+64.42%
1Y Performance:
+93.18%
1-Day Range:
$1.6021
$1.72
1-Week Range:
$1.45
$1.72
52-Week Range:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.71 | 102.47M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Prelude Therapeutics divulges new JAK2 inhibitors - BioWorld MedTech
It makes sense and dollars to buy Prelude Therapeutics Inc (PRLD) stock - setenews.com
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Prelude Therapeutics (PRLD) Reveals Promising Preclinical Data a - GuruFocus
Prelude Therapeutics Unveils Promising Preclinical Data for JAK2V617F-selective JH2 Inhibitor and mCALR-targeted Degrader Antibody Conjugate at ASH 2025 - Quiver Quantitative
Prelude Therapeutics (Nasdaq: PRLD) details MPN pipeline at 2025 ASH, eyes 2026 IND - Stock Titan
What insider trading reveals about Prelude Therapeutics Incorporated stockShort Setup & Daily Volume Surge Trade Alerts - Newser
VIX Spike: How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Decliners & Growth Focused Stock Pick Reports - moha.gov.vn
Growth Report: What dividend safety score for Prelude Therapeutics Incorporated stockJuly 2025 Big Picture & Daily Volume Surge Signals - moha.gov.vn
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo
Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Real time alert setup for Prelude Therapeutics Incorporated performanceProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MyChesCo
Using flow based indicators on Prelude Therapeutics Incorporated2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Taking on analysts’ expectations and winning: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges - MSN
Published on: 2025-11-16 22:10:23 - newser.com
What institutional flow reveals about Prelude Therapeutics IncorporatedJuly 2025 Earnings & Safe Capital Growth Tips - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Weekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
How to build a custom watchlist for Prelude Therapeutics IncorporatedJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pattern recognition hints at Prelude Therapeutics Incorporated upsideSwing Trade & Advanced Technical Analysis Signals - newser.com
How moving averages guide Prelude Therapeutics Incorporated tradingBuy Signal & Weekly Breakout Watchlists - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Volume spikes in Prelude Therapeutics Incorporated stock – what they meanMarket Performance Report & Daily Stock Momentum Reports - newser.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Q3 2025 Earnings Call Transcript - Insider Monkey
Will Prelude Therapeutics Incorporated stock deliver shareholder valueTrade Exit Summary & AI Forecast for Swing Trade Picks - newser.com
Published on: 2025-11-14 02:04:28 - newser.com
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):